Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J Young, Kelly Waldeck, Claire Martin, Jung H Foo, Donald P Cameron, Laura Kirby, Hongdo Do, Catherine Mitchell, Carleen Cullinane, Wendy Liu, Stephen B Fox, Ken Dutton-Regester, Nicholas K Hayward, Nicholas Jene, Alexander Dobrovic, Richard B Pearson, James G Christensen, Sophia Randolph, Grant A McArthur, Karen E Sheppard
Pigment Cell & Melanoma Research | WILEY-BLACKWELL | Published : 2014
Related Projects (1)
Awarded by National Health and Medical Research Council of Australia
The authors wish to thank David Byrne for assistance and expertise with histology and TMA creation and acknowledge the Australian Biospecimens Network Cell Line Bank at QIMR for the provision of many of the cell lines used in this study. Pfizer Oncology and funding from the National Health and Medical Research Council of Australia Grant # 1042986 to GAM and KES financially supported this work. NKH, GAM, and RBP are all supported by fellowships from the National Health & Medical Research Council of Australia.